OBJECTIVES: The development of new therapeutic targets is needed to change the current low survival rates of cancer of the oesophagus. In some clinical trials, angiogenic inhibitors, including those targeting the vascular endothelial growth factor (VEGF) and its receptors, have proven efficacious. In concert with this, neuropilin-1 (NRP1), a coreceptor for VEGF, is expressed by many tumours and may be related to their progression. This study aimed to assess the expression and prognostic value of fNRP1 in primary squamous cell carcinoma (SCC) of the oesophagus.
INTRODUCTION
Oesophageal cancer was estimated as the eighth most common cancer worldwide and the sixth most common cause of cancer deaths in 2008 [1] . Despite substantial improvements in screening, diagnosis, and treatment, oesophageal cancer continues to have a 5-year overall survival of <10% [2] . Therefore, there is a clear and urgent need to develop active new agents that might improve the current survival rates. Fortunately, the emerging understanding of the molecular pathways driving tumourigenesis has provided novel therapies including angiogenesis inhibitors [3] . Many of these reagents proved their clinical efficacy in advanced clinical trials, including those targeting vascular endothelial growth factor (VEGF) and its receptors [4] . Eventually, this contributed to FDA approval of several inhibitors of the VEGF pathway, which enabled prominent advances in anticancer therapy [5] .
Neuropilin-1 (NRP1), a transmembrane glycoprotein receptor, acts as a coreceptor for VEGF and increases the affinity for VEGF receptor 2 (VEGFR2) in endothelial [6] and tumour cells [7] . Through NRP1, VEGF stimulates endothelial cell migration and adhesion during the early stages of angiogenesis [8] . Some evidence suggests that NRP1 might be acting through mechanisms other than VEGFR2 [9] . Demonstrating the potential of the receptor as a therapeutic target [10] , preclinical studies reported that NRP1 is expressed by tumour cells and that it enhances tumour angiogenesis and tumour growth in many tumour models and cancer patients [7, 11, 12] . Based on these studies, a phase 1 clinical trial is currently underway to test the efficacy of an antibody against NRP1 (MNRP1685A, Genentech, Inc.) in patients with solid malignancies [13] .
Characterization of NRP1 expression is important to identify the indications where anti-NRP1 therapies may show clinical activity. Moreover, the precise response is likely to depend on the extent to which NRP1 is expressed. NRP1 expression analysis may identify prospectively planned biomarker studies, which may eventually lead to improved therapies. The aim of the current study was to provide a comprehensive analysis of the expression of NRP1 in oesophageal squamous cell carcinoma (SCC) and to get insight into its relationship with clinocopathological features.
PATIENTS AND METHODS

Patients
Sixty patients undergoing surgical resection for oesophageal carcinoma at the Tongji Hospital between November 2011 and January 2013 were prospectively enrolled in this study. This group consisted of 51 males (85%) and 9 females (15%). The average age at operation was 56.87 ± 6.78 years (range, 38-69). Prior to operation, none of the patients received chemo-or radiation therapy.
Tissue specimens harvesting
The performed protocol was approved by the institutional review board of Tongji Medical College. Informed consents were obtained from all involved patients. Paired primary oesophageal carcinomas and their matched adjacent normal oesophageal mucosal tissues were collected immediately after resection. Specimens were either immersed in 4% paraformaldehyde prior to paraffin embedding or stored at −80°C after harvesting until being processed for western blotting and/or real-time quantitative PCR (qPCR). Simultaneously, similar specimens were sent for routine histopathology analysis.
Clinical and histopathological assessment
Medical records were reviewed for all cases to obtain pertinent clinical information. Tumours were allocated into upper, middle or lower oesophagus according to the location of their proximal edges in relation to predetermined landmarks. Using endoscopic data, the vertical extension of the tumour was recorded and included as an additional indicator for tumour size. Histological grading was determined according to the criteria of the World Health Organization classification system [14] . All the patients were staged according to standardized recommendations of American Joint Committee on Cancer (AJCC) in its 7th edition of tumour-node-metastasis (TNM) staging manual [15] . Different clinical and pathological features of study population are summarized in Table 1 .
Immunohistological staining
Fixed tissues were placed in graded ethanol for dehydration, embedded in paraffin, sliced and de-waxed. Antigen retrieval was done by heating with ethylenediamine tetraacetic acid buffer for 10 min; endogenous perioxidase blocking was done by 3% hydrogen peroxide solution for 10 min at room temperature; blocking with 5% bovine serum albumin was done at 37°C for 20 min. Primary rabbit anti-human NRP1 monoclonal antibodies (Abcam, USA, ab81321, 1:100) were incubated overnight at 4°C. For chemical staining, Kit A solution of secondary antibodies (Dako REAL™ EnVision™ Detection System, Peroxidase/DAB+, Rabbit/Mouse, K5007) was incubated 45 min to 1 h at room temperature. Finally, staining by DAB solution and haematoxylin 1% hydrochloric acid was done followed by rehydration then mounting. Slides were checked under (Nikon Eclipse Ti-SR) microscope.
For fluorescence staining, 50-100 μl CY3 labelled goat antirabbit fluorescent secondary antibody ( Jackson Immunoresearch 111-165-003; 1:200) was incubated in the dark at room temperature for 50 min to 1 h. After incubation in DAPI (Beyotime, C1002) for 5 min to label the nucleus, cover slips were mounted with antifluorescence quench reagent (Beyotime, P0126). Sections were detected by fluorescence microscopy and images were taken through a (Nikon DS-U3) camera.
Western blotting
The most representative areas of frozen specimens were selected. Cell lysis buffer (Beyotime, China, P0013E) was added to get the total proteins. Their concentrations were determined using a protein assay Kit (Beyotime, P0012). Heating at 100°C for 5 min was done before separation by SDS-PAGE on 8% polyacrylamide gels and electroblotting onto transfer membrane (Roche, 03010040001). Non-specific binding was blocked by incubation for 1 h in 5% (w/v) non-fat milk. The primary antibodies were incubated overnight at 4°C including rabbit anti-human NRP1 monoclonal (Abcam ab81321, USA, 1:1000) and rabbit anti-human tubulin (Santa Cruz, USA sc-5546, 1:200). Bound antibodies were detected using secondary goat anti-rabbit antibodies labelled with horseradish peroxidase (KPL, USA, 074-1506, 1:3000). Finally, the blots were exposed by a chemiluminescence detection kit (Fisher Thermo Scientific, Inc., USA, PI34077). Samples obtained from the same subjects were processed at the same time and blot exposure time was fixed all through the sessions. Band densities were evaluated using image analysis software (ImageJ). NRP1 band densities in cancer and normal tissues were normalized to the tubulin of the same specimens. 
RNA isolation, reverse transcription and real-time PCR
Total RNA was isolated using a spin or vacuum total RNA isolation system (Promega, USA, Z3105); reverse transcription for cDNA synthesis was performed with 3 μg total RNA using RevertAid™ First Strand cDNA Synthesis Kits (Fermentas, Fisher thermo scientific, USA, K1622) with random primers. The used primer sequences were synthesized by Shanghai sangon Company including in China: CAGGTGATGACTTCCAGCTCA (forward) and CCCAGTGGCAGAAGGTCTTG (reverse) for isoform1 of human NRP1, in addition to GGTGGGCATCGACTCCTATG (forward) and AGTGAATAGGCTCCAGGCAG (reverse) for human tubulin. qPCR was performed on a Applied Biosystems model 7500 Fast PCR System using TaqMan universal PCR master mix (Applied Biosystems, 4364338) in a total volume of 50 μl. The condition for PCR programme was: 95°C for 10 min, followed by 40 cycles: 95°C for 10 s, and 60°C for 60 s. Tubulin was used as an endogenous reference gene to calculate the relative expression ratios of NRP1 using the ΔCT and 2^-ΔΔCT methods, respectively.
Statistical analysis
Statistical analysis was performed using (SPSS 18, Chicago, IL, USA). Independent and paired T tests were used for data with normal distribution and data with skewed distribution (NRP1 values of normal specimens and cancer/normal NRP1 ratios) after natural logarithm transformation. Non-parametric (Kruskal-Wallis and MannWhitney) tests were used for data with a skewed distribution.
In cross tables, χ 2 and Fisher's exact tests were used with the nominal independent variables while, non-parametric tests were used with the ordinal independent variables. Additionally, regression analysis was done to assess the dependency of clincopathological variables on NRP1 levels. A value of P < 0.05 was considered to be statistically significant.
RESULTS
Localization of NRP1 expression
Cancer specimens demonstrated positive NRP1 staining (n = 10) in the endothelium of tumour vasculatures as well as in the malignant cells. Some of those NRP1-positive cells expressed NRP1 on their cell surfaces, particularly large-sized cells (Fig. 1A  and B) , while others showed either diffuse cytoplasmic or localized perinuclear expression.
In contrast, positive NRP1 staining was not evident in normal oesophageal mucosal epithelium, apart from occasional basal squamous cells and submucosal vasculatures. Oesophageal mucous glands of lamina propria showed no positive staining ( Fig. 2A and 2B) .
Total NRP1 expression pattern in squamous cell carcinoma
Values for NRP1 expression were represented by the optical density of the immunoblots in relation to tubulin. All of the 60 SCC and their corresponding normal specimens showed variable degrees of NRP1 expression. Our data analysis did not identify any relationship between (cancer and normal) NRP1 levels and patient age, sex or the site of oesophagus from where the samples were taken. NRP1 expression values in SCC (1.468 ± 0.733) were more than two times higher than in normal mucosa (0.720 ± 0.613) (P = 0.0001) (Fig. 3A) . NRP1 was overexpressed in 81.7% (49 of 60) of the cancer samples. The mean cancer to normal ratio was 3.647 ± 0.48.
Higher molecular weight NRP1 expression in squamous cell carcinoma
The proportion of SCC samples expressing mNRP1 (85%; 51 of 60) was significantly higher (P = 0.001) than the mNRP1-positive proportion of the corresponding normal specimens (58.3%; 35 of 60). Additionally, mNRP1-positive specimens' expression of mNRP1 was more than three times higher (P = 0.001) in the cancer group (1.03364 ± 2.596) compared with the normal group (0.2761 ± .9653). For mNRP1-positive specimens, mNRP1 predominantly represented (71.51 ± 20.6%) of total NRP1 in the cancer group, which is higher (P = 0.003) than in the normal group (58.55 ± 23.17%) (Fig. 3C ). NRP1-mRNA expression in squamous cell carcinoma NRP1-mRNA expression was analysed by qPCR and represented by its relative expression in relation to tubulin. NRP1-mRNA in cancer specimens (0.4348 ± 0.5217) was significantly higher than their matched normal specimens (0.2049 ± 0.3224) (n = 16, P = 0.0204). Ratios of cancer/normal NRP1 expression (3.740 ± 3.669) were compatible with those obtained using western blot analysis (3.778 ± 2.120) (n = 16, P = 0.9737). This means that the variations in protein levels were accompanied by similar variations in mRNA levels (Fig. 3B) .
Relationship between SCC-NRP1 and the clincopathological parameters
Tumours were classified according to cancer/normal NRP1 ratio (c/n NRP1). Tumours were either positive or negative for NRP1 overexpression (overexpression was defined by c/n NRP1 >1). Moreover, using cut-off points of 1.5 and 4 (corresponding to the 25th and 75th percentiles of c/n NRP1 values, respectively), tumours were classified into low (c/n NRP1 < 1.5), moderate (c/n NRP1≥1.5 and ≤4) and high (c/n NRP1>4) grades of relative expression. On the other hand, tumours were also classified according to the presence and absence of mNRP1 into mNRP1 -positive and -negative groups.
Patient clinicopathological features [age, sex, tumour site, grade, tumour invasion (T), nodal invasion (N), tumour extension (Ext.) and prognostic TNM staging ( pTNM)] were analysed in relation to NRP1 overexpression (negative or positive), the presence of mNRP1 (negative or positive) and different grades of relative NRP1 overexpression (low, moderate and high) and summarized in Table 2 .
The results showed that overexpression of NRP1 was significantly correlated with the depth of tumour invasion (P = 0.050), and tumour site (P = 0.040), whereas it had no relation with histological grade (Fig. 3D) , pTNM or other parameters. Moreover, tumours with overexpressed NRP1 had more than a four times tendency towards high invasiveness than the other tumours (P = 0.018 and Odd's ratio = 4.8).
In parallel, analysis of our data demonstrated that mean values of NRP1 expression for tumours allocated to Groups T3 and 4 with higher wall invasion potential (0.48 ± 0.35, n = 25) were almost two times higher than those allocated to T1 and 2 (0.26 ± 0.44, n = 35) (P = 0.034). This suggests that NRP1 overexpression may be a putative factor in the promotion of the invasive behaviour and supports the potential role of NRP1 in SCC progression. The grades of NRP1 overexpression for the 60 tumour specimens did not show significant difference in relation to the other features apart from tumour location. However, we observed a trend towards correlation between a fhigh grade of NRP1 overexpression and the deeper wall invasion that did not reach statistical significance (P = 0.096).
On the other hand, on comparing the distribution of mNRP1-positive and -negative subjects within different clinicopathological categories, mNRP1 positive tumours were significantly correlated with lack of lymph node metastasis (P = 0.036) and better prognostic TNM stages (P = 0.037), but not with the other parameters. Those tumours with low pTNM stages and no local lymph node affection demonstrated positive mNRP1 expression more frequently. In accordance with these findings, regression analysis showed that tumours with negative mNRP1 had higher risk for more lymph node invasion (P = 0.041, O.R = 4.250) and late prognostic TNM stages (P = .050, O.R = 4.491) than those with positive mNRP1 (Fig. 3D) .
DISCUSSION
Numerous studies have reported expression patterns of NRP1 in human cancers, including colorectal [16] , breast [17] , stomach [6] and lung cancer [11] . In many of them, the higher expression has been correlated with tumour progression and/or poorer prognosis. Hansel et al. [16] previously identified NRP1 overexpression in a subset of dysplastic lesions of the gastrointestinal tract including oesophagus. Normal and low-grade dysplasia did not contain detectable NRP1 expression; 50% of high-grade dysplasia showed focal positivity and increasingly all invasive adenocarcinomas (AC) showed high positivity. As the potential influence of the histology should not be ignored, we tried to confirm these findings in SSC. Unlike in the western countries, where AC constitutes approximately half of all oesophageal cancer cases, SCC continues to be the dominant type in china, where we conducted our study [18] .
We identified additional higher molecular weight NRP1 bands (Fig. 3D ) similar to the bands reported by Frankel et al. [19] in diverse human tumour cell lines; this high molecular weight NRP1 was modified by the addition of Chondroitin sulphate glucosaminoglycans (GAG) to a single conserved serine residue (Ser 612). Additionally, Shintani et al. [20] reported such bands in vascular endothelial and smooth muscle cell cultures, which were modified by heparin sulphate and Chondroitin sulphate GAG. Here, we refer to such bands as modified NRP1 (mNRP1) even though other mNRP1 comprising N-linked glycosylated core protein may reside within the band with expected molecular weight for NRP1 (<150 k Da).
In the AVAGAST trial, a prespecified correlation between biomarkers and clinical outcome was assessed. NRP1 expression was found to be a biomarker to evaluate overall survival and the response to anti-VEGF therapy in gastric adenocarcinoma [21] . Our findings in oesophageal SCC are consistent with the previously reported association of NRP1 with tumourigenesis or angiogenesis as a cancer invasion enhancer. On the other hand, the association of NRP1 with clinical outcome is less clear and our NRP1 expression levels, reflecting the NRP1 content of the malignant cells and tumour vasculature as well, showed no correlation with tumour cells differentiation or other tumour features. Controversially, tumours with positive mNRP1 were associated with less nodal affection and favourable prognostic stages. The mechanism by which GAG addition to NRP1 can change its biological action and subsequently the invasive behaviour of the tumour is unknown and still needs to be identified. Although the pathological and clinical parameters we used were our best available prognostic markers, they remain suboptimal for the accurate prediction of an individual's overall survival [1] .
In accordance with our findings that the presence of mNRP1 may have some limiting effects on tumour progression, Frankel et al. [16] reported that Chondroitin sulphate-mNRP1 modulates three-dimensional (3D) invasion in the human glioblastoma cell line (U87MG), and the (unmodified) S612A NRP1 mutant but not the wild-type NRP1 in the (U87MG) cells leads to enhanced cell invasion in a 3D matrix. However, the role of mNRP1 remains unclear and needs further studies to be elucidated.
CONCLUSION
NRP1 is overexpressed in SCC and may contribute to local tumour invasiveness. The presence of the GAG-mNRP1 receptor carries less potential for node metastasis and a better prognostic stage, suggesting that the balance between modified and unmodified NRP1 might be important for determining the invasive potential of oesophageal SCC. These observations might assist the current research for new therapeutic targets.
